Filing Flows › Iovance Biotherapeutics (IOVA) › Q2 2026
Iovance Biotherapeutics (IOVA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Iovance Biotherapeutics (IOVA) reported revenue of $99.3M for the second quarter 2026 (Q2 2026), +66% from a year earlier and +39% from the quarter before. Operating margin was -52.3%, net loss $47.3M (47.6% of revenue).
Iovance Biotherapeutics, Q2 2026: revenue $99.3M (+66% year over year), operating margin -52.3%, net loss $47.3M, operating cash flow −$60.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $99.3M | +39% | +66% |
| Operating profit | −$51.9M | — | — |
| Net earnings | −$47.3M | — | — |
| Operating cash flow | −$60.8M | — | — |
What changed
Revenue was $99.3M in Q2 2026, up 66% year over year and up 39% from the previous quarter. Amtagvi was the largest line at 91% of revenue. Amtagvi added $36.6M year over year (up 68%), 93% of the total change.
Operating costs exceeded revenue by $51.9M, an operating margin of -52.3%. Total costs fell 13% while revenue rose 66%. The quarter ended with a net loss of $47.3M, narrower than the previous quarter's $79.0M loss.
Operating cash flow was −$60.8M. Non-cash charges added back $3.8M of depreciation and amortization and $11.7M of share-based compensation. Working capital and other items used $29.0M. Capital expenditures of $5.4M exceeded it, leaving free cash flow of −$66.3M.
Questions
What was Iovance Biotherapeutics' revenue in the second quarter 2026?
Iovance Biotherapeutics (IOVA) reported revenue of $99.3M for the second quarter 2026 (Q2 2026), +66% from a year earlier and +39% from the quarter before.
Was Iovance Biotherapeutics profitable in the second quarter 2026?
Operating loss was $51.9M (-52.3% of revenue) and net loss $47.3M.